We are a Nordic biotech company that, with our hub & spoke business model, develop and add value to our group's project portfolio through separate portfolio companies. This gives us the right conditions to run the projects with lower costs, increased focus and provides a more efficient exit process. Among other things, the projects have in common that they must have a significant commercial potential, a clearly defined medical need and the potential for an early exit.


Our portfolio companies

With our three portfolio companies, we have a total pipeline of four projects ready to enter clinical phase IIa and phase IIb in skin cancer, hair loss and chronic wounds, as well as one project in leukemia that is being prepared for clinic.

Avexxin Oncology focuses on the development of new innovative drugs in inflammation-driven cancer.

Read more on avexxinoncology.com

Follicum focuses on the development of new and ground-breaking treatments for hair loss and chronic wounds.

Read more on follicum.com

Reccura Therapeutics focuses on being able to offer a unique and well-tolerated treatment for both actinic keratosis and basal cell carcinoma.

Read more on reccuratherapeutics.com

Our research

In our total project portfolio, we have seven pharmaceutical projects, four of which are ready for phase IIa or phase IIb. What the projects have in common is that they are based on two unique validated technology platforms resting on solid research and collaborations with pioneering and internationally recognized researchers and academics.

Latest news

Upcoming events

Annual report 2022
Interim report Q1 2023
More events

Coegin News

Se all Episodes

Team Coegin

Our management team has extensive experience in drug development, commercialization and business scale-up.

meet the team
Tore Duvold


Lars Bukhave Rasmussen


Berit Johansen


Kristian Lykke Fick


John Zibert